Surmodics 8-K announces Q3 FY25 results via Exhibit 99.1

Rhea-AI Filing Summary

On 8 Aug 2025 Surmodics, Inc. (SRDX) filed a Form 8-K to furnish a press release announcing its financial results for the quarter ended 30 Jun 2025. The press release is attached as Exhibit 99.1, but the filing itself contains no revenue, EPS, balance-sheet or guidance figures. The disclosure falls under Item 2.02 (Results of Operations and Financial Condition) and is expressly marked as “furnished,” not “filed,” which limits Section 18 Exchange Act liability. Aside from the exhibit list and standard representations, the document offers no additional financial data or strategic commentary.

Insights

Financial Analyst

TL;DR: Routine 8-K furnishes earnings press release; no numbers disclosed; neutral investor impact.

This Form 8-K simply notifies investors that Surmodics has released its quarter-ended 30 Jun 2025 results via Exhibit 99.1. Because the exhibit content is not included here, investors gain no visibility into revenue trends, profitability, or guidance. The information is also classified as “furnished,” further underscoring its procedural nature. In the absence of hard data, the filing neither alters valuation assumptions nor signals material risk or opportunity. Impact is best described as administrative.

0000924717false00009247172025-08-082025-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 08, 2025

Surmodics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Minnesota			0-23837	41-1356149
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
9924 West 74th Street
Eden Prairie, Minnesota				55344
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 952 500-7000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.05 par value		SRDX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2025, Surmodics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the full text of the Press Release is furnished as Exhibit 99.1 to this report.

The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated August 8, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SURMODICS, INC.
Date:	August 8, 2025	By:	/s/ Timothy J. Arens
			Timothy J. Arens Senior Vice President of Finance and Chief Financial Officer

FAQ

What form did Surmodics (SRDX) file on August 8, 2025?

Surmodics filed a Form 8-K current report.

What event triggered the SRDX Form 8-K filing?

The company issued a press release announcing financial results for the quarter ended June 30, 2025.

Which exhibit contains Surmodics’ Q3 FY25 press release?

The press release is provided as Exhibit 99.1 to the Form 8-K.

Does the 8-K include actual financial statements or metrics?

No. The filing states results were released but does not include any financial figures within the document.

What is Surmodics’ trading symbol and exchange?

Surmodics trades under SRDX on the Nasdaq Global Select Market.